CHANDAN HEALTHCARE LIMITED

Reg Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021
CIN: L85110UP2003PLC193493
TEL NO.: -8069366666 **Email:** secretarial@chandan.co.in
www.chandandiagnostic.com

Date: 10-08-2026

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (East), Mumbai – 400051

SYMBOL: CHANDAN
ISIN: INE0B2N01016

Subject: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Administrative Warning Letter received from SEBI

Dear Sir/Madam,

Pursuant to **Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015** ("SEBI LODR Regulations"), we hereby inform you that **Chandan Healthcare Limited ("Company") has received an Administrative Warning Letter dated 06 August 2026**, bearing reference no. **HO/49/13/11(418)2026-CFD-SEC-5/18266/2026**, from the Securities and Exchange Board of India ("SEBI"). A copy of warning letter is also enclosed as an **Annexure-B.**

Background of the Matter

The Company submits, for completeness and to place the matter in its proper context, that the aforesaid matter had originated pursuant to a **complaint/representation made by Dayal Institute of Medical Sciences Limited (formerly Chandan Institute of Medical Sciences Limited) ("DIMS") made before the concerned regulatory authorities, including SEBI**.

Subsequently, **DIMS withdrew the said complaint/representation before the concerned regulatory authorities, including SEBI**, and the said withdrawal was also disclosed by the Company to the Stock Exchange vide its earlier communication dated **31 July 2026**.

No monetary penalty or restriction has been imposed on the Company pursuant to the aforesaid Administrative Warning Letter.

The details prescribed under Regulation 30 of the SEBI LODR Regulations are enclosed herewith as **Annexure A**.

With reference to above, the Company shall ensure compliance with the regulation and exercise due caution to avoid recurrence of such events.

This is for your information and records.

Thanking You,

For Chandan Healthcare Limited

RAJEEV NAIN
Digitally signed by RAJEEV NAIN
Date: 2026.08.10 16:30:12 +05'30'

Rajeev Kumar Nain
Company Secretary & Compliance Officer

Annexure- A

Form-A

Disclosure of information pursuant to Regulation 30 of the Listing Regulations read with the SEBI Master Circular No.: HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026:

Sr. No.	Particulars	Details
1	**Name of the listed company**	Chandan Healthcare Limited
2	**Type of communication received**	Administrative Warning Letter
3	**Date of receipt of communication**	06-Aug-2026
4	**Authority from whom communication received**	Securities and Exchange Board of India (SEBI)
5	**Brief summary of the material contents of the communication**	SEBI, pursuant to its examination in the matter of the Initial Public Offer of the Company, has observed that the Company had failed to make true and adequate disclosures in the Red Herring Prospectus with respect to partly paid-up shares held by DIMS. SEBI has accordingly issued an Administrative Warning to the Company and its Board of Directors and advised them to exercise due care in future to avoid recurrence of such lapses.
6	**Period for which such communication is applicable, if stated**	Not Applicable
7	**Expected financial implications, if any**	No material financial implication is expected on the Company.
8	**Details of any aberrations/non-compliances in relation thereto**	SEBI has observed that the Company had failed to make true and adequate disclosures in the RHP with respect to partly paid-up shares held by Dayal Institute of Medical Sciences Limited (formerly Chandan Institute of Medical Sciences Limited
9	**Details of any penalty, restriction or sanction imposed pursuant to the communication**	No monetary penalty or restriction has been imposed on the Company. The communication is in the nature of an Administrative Warning.
10	**Details of any action taken by the listed entity with respect to the communication**	The Company has taken note of the observations made by SEBI and shall exercise due caution and strengthen its internal review and verification mechanism for regulatory and statutory disclosures to avoid recurrence of such lapses. The matter shall also be placed before the Board of Directors at its ensuing meeting for consideration and appropriate directions.
11	**Any other relevant information**	The matter had originated pursuant to a complaint/representation made by DIMS before the concerned regulatory authorities, including SEBI. Subsequently, DIMS withdrew the said complaint/representation before the concerned regulatory authorities, including SEBI. The said withdrawal was also disclosed by the Company to the Stock Exchange vide its earlier communication dated 31 July 2026. Notwithstanding the withdrawal, SEBI proceeded with its examination of the matter and issued the aforesaid Administrative Warning Letter.

भारतीय प्रतिभूति और विनिमय बोर्ड
Securities and Exchange Board of India

Chief General Manager
Supervision Enforcement and Complaints (SEC-5)
Corporation Finance Department (CFD)

HO/49/13/11(418)2026-CFD-SEC5-I/18266/2026
August 06, 2026

Chandan Healthcare Limited,
Biotech Park, Sector G, Jankipuram,
Kursi Road, Lucknow – 226021.

Sir,

Kind Attention: Shri. Rajeev Kumar Nain, Company Secretary and Compliance Officer

Sub: Administrative Warning – Non-compliance with the provisions of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("ICDR Regulations") in the matter of Chandan Healthcare Limited.

1. During the examination in the matter of IPO of Chandan Healthcare Limited ("the Company"), it is observed that you have failed to make true and adequate disclosures in RHP w.r.t. partly paid up shares held by Chandan Institute of Medical Sciences Limited.

2. The above non-compliance has been viewed seriously. Accordingly, the company and its Board of Directors are hereby warned and advised to be careful in future to avoid recurrences of such lapses. Any repetition of the such violation in future will be viewed seriously and appropriate enforcement action would be initiated in accordance with the provisions of the SEBI Act, 1992, the Rules, the Regulations or Circulars issued thereunder.

3. You are also advised to place this communication before your board of directors in the upcoming board meeting and forward their comments to SEBI, as to whether they are satisfied with the corrective steps taken in ensuring future compliance.

4. You are also advised, to disclose the instant administrative warning letter to the stock exchange under Regulation 30 of the LODR Regulations, 2015.

Yours faithfully,

Nirmal Mehrotra

Nirmal Mehrotra

भारतीय प्रतिभूति और विनिमय बोर्ड SEBI Securities and Exchange Board of India